<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305812</url>
  </required_header>
  <id_info>
    <org_study_id>MY11</org_study_id>
    <secondary_id>CAN-NCIC-MY11</secondary_id>
    <secondary_id>CELGENE-CAN-NCIC-MY11</secondary_id>
    <secondary_id>CDR0000466184</secondary_id>
    <nct_id>NCT00305812</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma</brief_title>
  <official_title>A Randomized Phase II Dose Finding Study of Revlimid™ and Melphalan in Patients With Previously Untreated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the&#xD;
      cancer. It may also stimulate the immune system in different ways and stop cancer cells from&#xD;
      growing. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the&#xD;
      growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving&#xD;
      lenalidomide together with melphalan may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying the side effects and best dose of&#xD;
      lenalidomide when given together with melphalan and to see how well they work in treating&#xD;
      patients with multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the tolerability of 2 different doses of lenalidomide when administered with&#xD;
           melphalan in patients with previously untreated multiple myeloma who are not planning to&#xD;
           undergo future autologous stem cell transplantation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Characterize the toxicity profile of lenalidomide in combination with melphalan.&#xD;
&#xD;
        -  Determine tumor response in these patients after 2 and 12 courses of induction therapy&#xD;
           with lenalidomide and melphalan and after 6 months of maintenance therapy with&#xD;
           dexamethasone.&#xD;
&#xD;
        -  Determine progression-free and overall survival of these patients.&#xD;
&#xD;
        -  Determine time to dose modification and time to dose discontinuation in these patients.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Examine wnt pathway inhibition in response to lenalidomide on pre- and post-treatment&#xD;
           bone marrow and blood samples using enzyme-linked immunosorbent assay (ELISA), gene&#xD;
           expression profiling, drosophila-based chemical genetics, and surface-enhanced laser&#xD;
           desorption/ionization mass spectrometry (SELDI MS) proteomics.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, open-label, dose-finding study of lenalidomide.&#xD;
&#xD;
      Prior to randomization, 6 patients receive oral lenalidomide at a lower dose (same dose to be&#xD;
      used in arm I) once daily on days 1-21 and oral melphalan once daily on days 1-4. Treatment&#xD;
      repeats every 28 days for 3 courses. If no unacceptable toxicity occurs, the trial will&#xD;
      proceed and randomization will occur.&#xD;
&#xD;
        -  Induction therapy: Patients are randomized to 1 of 2 dose levels of lenalidomide.&#xD;
&#xD;
             -  Arm I: Patients receive oral lenalidomide once daily on days 1-21 and oral&#xD;
                melphalan once daily on days 1-4.&#xD;
&#xD;
             -  Arm II: Patients receive oral lenalidomide as in arm I, but at a lower dose, and&#xD;
                melphalan as in arm I, but at a higher dose.&#xD;
&#xD;
      Treatment in both arms repeats every 28 days for up to 12 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. After 12 courses of induction therapy, patients in both&#xD;
      arms without progressive disease proceed to maintenance therapy.&#xD;
&#xD;
        -  Maintenance therapy: Patients receive oral dexamethasone once daily on days 1-4. Courses&#xD;
           repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks and then every 2 months&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 92 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2005</start_date>
  <completion_date type="Actual">June 30, 2008</completion_date>
  <primary_completion_date type="Actual">June 30, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity within first 3 courses of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response after 2 courses, 6 courses, 12 courses, and 6 months of maintenance therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease-free interval</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to dose modification</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to dose discontinuation</measure>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed multiple myeloma by one of the following:&#xD;
&#xD;
               -  Biopsy of an osteolytic lesion or soft tissue tumor composed of plasma cells&#xD;
&#xD;
               -  Bone marrow aspirate and/or biopsy demonstrating ≥ 10% plasmacytosis&#xD;
&#xD;
               -  Bone marrow &lt; 10% plasma cells but with ≥ 1 bony lesion AND meets the M-protein&#xD;
                  criteria&#xD;
&#xD;
          -  Ineligible for stem cell transplantation due to any of the following:&#xD;
&#xD;
               -  Advanced age&#xD;
&#xD;
               -  Comorbid illness&#xD;
&#xD;
               -  Patient preference&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Measurable (i.e., quantifiable) serum M-component of IgG, IgA, IgD, or IgE at initial&#xD;
             diagnosis OR, if only light-chain disease is present (urine M-protein only), urinary&#xD;
             excretion of light-chain protein (Bence Jones) ≥ 1.0 g/24 hours at initial diagnosis&#xD;
&#xD;
               -  No nonsecretory myeloma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 150,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST and/or ALT ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 methods of effective contraception during and for 4 weeks&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No other malignancies within the past 5 years, except adequately treated nonmelanoma&#xD;
             skin cancer or curatively treated in situ cancer of the cervix&#xD;
&#xD;
          -  No hypersensitivity to thalidomide or its components, including the development of a&#xD;
             desquamating rash&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No history of significant neurologic or psychiatric disorder that would preclude&#xD;
             informed consent&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction,&#xD;
             including any of the following:&#xD;
&#xD;
               -  Significant cardiac event (including symptomatic heart failure or angina) within&#xD;
                  3 months prior to randomization&#xD;
&#xD;
               -  Any cardiac disease that increases risk for ventricular arrhythmia&#xD;
&#xD;
               -  History of ventricular arrhythmia that was symptomatic or required treatment,&#xD;
                  including any of the following:&#xD;
&#xD;
                    -  Multifocal premature ventricular contractions&#xD;
&#xD;
                    -  Bigeminy&#xD;
&#xD;
                    -  Trigeminy&#xD;
&#xD;
                    -  Ventricular tachycardia/fibrillation/flutter/arrhythmia NOS&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or corticosteroids for the treatment of multiple myeloma&#xD;
&#xD;
               -  Prior corticosteroids for the treatment of hypercalcemia or spinal cord&#xD;
                  compression allowed provided maximum levels have not been reached (i.e.,&lt; 120 mg&#xD;
                  for dexamethasone or &lt; 792 mg for prednisone)&#xD;
&#xD;
          -  Prior radiotherapy to single sites for pain control or local plasmacytoma allowed&#xD;
&#xD;
          -  Prior or concurrent bisphosphonates allowed&#xD;
&#xD;
          -  At least 28 days since prior investigational anticancer agents or therapy&#xD;
&#xD;
          -  No concurrent corticosteroids above physiologic replacement doses&#xD;
&#xD;
          -  Concurrent radiotherapy to sites of active myeloma with pain or neurologic compromise&#xD;
             allowed&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF) on day 1 of course 1&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell White, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Nova Scotia Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute at University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Cancer Program at Sault Area Hospital</name>
      <address>
        <city>Sault Ste. Marie</city>
        <state>Ontario</state>
        <zip>P6A 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital - Weston</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre at Pasqua Hospital</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>White DJ, Paul N, Macdonald DA, Meyer RM, Shepherd LE. Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial. Curr Oncol. 2007 Apr;14(2):61-5.</citation>
    <PMID>17576467</PMID>
  </reference>
  <results_reference>
    <citation>White DJ, Bahlis NJ, Marcellus DC, et al.: Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: the NCIC CTG MY.11 trial. [Abstract] Blood 112 (11): A-2767, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>White DJ, Kovacs MJ, Belch A, et al.: Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: toxicity data from the NCIC CTG MY.11 trial. [Abstract] Blood 110 (11): A-189, 2007.</citation>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 21, 2006</study_first_submitted>
  <study_first_submitted_qc>March 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2006</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

